Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

ClinicalTrials.gov ID: NCT01514149

Public ClinicalTrials.gov record NCT01514149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy

Study identification

NCT ID
NCT01514149
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ConjuChem
Industry
Enrollment
73 participants

Conditions and interventions

Interventions

  • CJC-1134-PC Injection Drug
  • Weekly placebo for CJC-1134-PC Injection Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2011
Primary completion
Apr 30, 2012
Completion
Feb 28, 2013
Last update posted
Jul 18, 2017

2011 – 2013

United States locations

U.S. sites
19
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Research Site Phoenix Arizona 85018
Research Site Inglewood California 90301
Research Site Tarzana California 91356
Research Site Ventura California 93003
Research Site Wellington Florida 33414
Research Site Idaho Falls Idaho 83404
Research Site Lexington Kentucky 40504
Research Site Brighton Massachusetts 02135
Research Site Greensboro North Carolina 27405
Research Site Eugene Oregon 97401
Research Site Altoona Pennsylvania 16602
Research Site East Providence Rhode Island 02915
Research Site Charleston South Carolina 29407
Research Site Taylors South Carolina 29687
Research Site Austin Texas 78758
Research Site Dallas Texas 75231
Research Site San Antonio Texas 78249
Research Site Salt Lake City Utah 84107
Research Site Henrico Virginia 23233

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01514149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 18, 2017 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01514149 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →